Results 211 to 220 of about 21,604,258 (289)

Designed Peptide Coacervates for Extracellular Antibody Targeting

open access: yesSmall, EarlyView.
Peptide‐based coacervates formed by liquid‐liquid phase separation provide a membraneless platform for therapeutic antibody delivery. Using Rituximab as a model, these coacervates enable efficient encapsulation, enhanced cell interactions, and provide partial protection from enzymatic proteolysis while maintaining low cytotoxicity.
Nofar Berman   +4 more
wiley   +1 more source

IFNγ-induced antigen loss in chimeric antigen receptor-T cell therapy. [PDF]

open access: yesFront Immunol
Cao M   +10 more
europepmc   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

open access: yesSmart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou   +4 more
wiley   +1 more source

Advances in research on layered double hydroxides for biomedical applications

open access: yesSmart Molecules, EarlyView.
Layered double hydroxides (LDHs) are pH‐responsive nanomaterials with broad biomedical applications. This review summarizes LDH synthesis methods and compares their advantages. It highlights LDHs' progress in cancer therapy, including chemo‐photothermal, chemo‐immunotherapy, and photodynamic‐immunotherapy combinations and their potential in bone repair.
Xinhui Yang   +13 more
wiley   +1 more source

Efficacy and safety of chimeric antigen receptor T-cell therapy for plasma cell leukemia. [PDF]

open access: yesHaematologica
Hu C   +12 more
europepmc   +1 more source

Dynamic risk stratification using early CAR‐T expansion in R/R LBCL treated with axicabtagene ciloleucel

open access: yesBritish Journal of Haematology, EarlyView.
Higher chimeric antigen receptor‐T expansion at day 7 is associated with improved progression‐free survival but also increased toxicity in axi‐cel treated patients with R/R large B‐cell lymphoma, independent of other baseline patient and disease characteristics.
Brydon Panozzo   +17 more
wiley   +1 more source

Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination. [PDF]

open access: yesNat Commun
Warmuth L   +24 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy